ABOUT AM-PHARMA
AM-Pharma is a leader in the development of a treatment for Acute Kidney Injury (AKI) that could be life-saving. Utilizing a concept-to-clinic approach, we have designed and developed an innovative recombinant human Alkaline Phosphatase (AP) therapeutic (recAP) from scientific research to successful Phase II clinical trials in patients with sepsis-associated AKI.
OUR MISSION
AKI is a devastating disease with high mortality rates and without approved pharmacological treatments, affecting millions of patients worldwide. Our mission is to change the treatment paradigm for patients with AKI and transform their prospects by developing and commercializing recAP, a proprietary disease-modifying biological drug.
